Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=11965227&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
The expanding role of epirubicin in the treatment of breast cancer Gluck SCancer Control 2002[Mar]; 9 (2 Suppl): 16-27Adjuvant treatment of early breast cancer has experienced major changes in the last 25 years. Since the mid 1970s, when cyclophosphamide, methotrexate and fluorouracil (CMF) resulted in statistically significant and clinically meaningful improvements in disease-free and overall survival, the use of adjuvant chemotherapy has become common practice worldwide. Anthracyclines are considered to be among the most active available agents to treat breast cancer and have become core components of adjuvant regimens. Anthracycline-containing polychemotherapy regimens provide a significant benefit over CMF. Regimens containing epirubicin are generally associated with prolongation in relapse-free and overall survival rates compared with standard therapies including CMF. Epirubicin-taxane combinations are active in treating metastatic breast cancer and do not appear to be associated with any pharmacokinetic interactions. Ongoing research is focusing on combining anthracyclines with taxanes in an effort to continue to improve outcomes following adjuvant therapy.|*Neoadjuvant Therapy[MESH]|*Taxoids[MESH]|Antibiotics, Antineoplastic/*administration & dosage[MESH]|Antineoplastic Agents, Phytogenic/administration & dosage[MESH]|Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use[MESH]|Breast Neoplasms/*drug therapy/pathology[MESH]|Bridged-Ring Compounds/administration & dosage[MESH]|Cyclophosphamide/administration & dosage[MESH]|Disease-Free Survival[MESH]|Docetaxel[MESH]|Doxorubicin/administration & dosage[MESH]|Epirubicin/*administration & dosage[MESH]|Female[MESH]|Fluorouracil/administration & dosage[MESH]|Humans[MESH]|Methotrexate/administration & dosage[MESH]|Paclitaxel/administration & dosage/*analogs & derivatives[MESH]|Prognosis[MESH]|Quality of Life[MESH]|Randomized Controlled Trials as Topic[MESH] |
